1. 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel. (September 2015) Authors: Grenader, T.; Ruszniewski, P.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Lang, A.; Gomez-Panzani, E.; Caplin, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours. (September 2015) Authors: Phan, A.; Caplin, M.; Pavel, M.; Cwikła, J.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours. (September 2015) Authors: Wolin, E.; Caplin, M.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3227 A phase II trial of ofatumumab for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) - An interim analysis. (September 2015) Authors: Kiesewetter, B.; Mayerhoefer, M.E.; Dolak, W.; Simonitsch-Klupp, I.; Lukas, J.; Raderer, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial. (September 2015) Authors: Prager, G.; Unseld, M.; Waneck, F.; Raderer, M.; Krainer, M.; Fuereder, T.; Hejna, M.; Staber, P.; Scheithauer, W.; Schmidinger, M.; Thallinger, C.; Farkas, L.; Reinthaller, A.; Polterauer, S.; Wrba, F.; Muellauer, L.; Mader, R.; Zielinski, C.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. (September 2015) Authors: Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.; Van Cutsem, E.; Tesselaar, M.E.T.; Shimada, Y.; Oh, D.Y.; Strosberg, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CLARITHROMYCIN AS a "REPURPOSING DRUG" AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL). (June 2017) Authors: Ferreri, A.J.; Cecchetti, C.; Kiesewetter, B.; Sassone, M.; Calimeri, T.; Perrone, S.; Ponzoni, M.; Raderer, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA. (12th June 2019) Authors: Raderer, M.; Dolak, W.; Simonitsch‐Klupp, I.; Kiesewetter, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT. (12th June 2019) Authors: Conconi, A.; Thieblemont, C.; Cascione, L.; Torri, V.; Kiesewetter, B.; Margiotta‐Casaluci, G.; Gaidano, G.; Raderer, M.; Cavalli, F.; Lopez Guillermo, A.; Johnson, P.W.; Zucca, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FIRST LINE SYSTEMIC TREATMENT IN MUCOSA‐ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA NOT ELIGIBLE FOR H. PYLORI ERADICATION – DO WE NEED CHEMOTHERAPY?. (12th June 2019) Authors: Kiesewetter, B.; Lamm, W.; Mayerhoefer, M.E.; Dolak, W.; Lukas, J.; Simonitsch‐Klupp, I.; Raderer, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗